ASP Isotopes 3Q 2026: Revenue $5.12M, EPS ($0.21) — 10-Q Summary

ASP Isotopes reported 3Q 2026 revenue of $5.12M, up 303% YoY, driven by radiopharmacy sales and new LNG revenue. However, net loss widened to $30.37M, with higher operating and interest expenses. Gross profit improved, but helium and LNG segment recorded a $0.8M loss. Isotope shipments are planned for 2026-2027, with LNG margins expected to improve in 2027.

Original reporting
Published Nov 16, 2026, 11:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:43 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ASP Isotopes 3Q 2026: Revenue $5.12M, EPS ($0.21) — 10-Q Summary — source image
Decision brief

The 30-second read

$ASPINeutralLow
01

Why it matters

Radiopharmacy revenue rose sharply with improved gross margin, while helium/LNG remained loss-making with negative gross margin. The company also notes Phase 1 commercial LNG operations started and expects margin improvement in 2027 as volumes increase.

02

Market read

Traders may reassess near-term profitability risk versus longer-dated margin improvement tied to LNG volume ramp and isotope shipment timing.

03

What to watch

The article flags helium and LNG as still below fixed-cost absorption levels, so near-term valuation may hinge more on volume ramp execution than on current revenue growth.

Relevance 4/10Novelty 3/10Timing: after-hours filing summary, for positioning ahead of follow-on analyst review

Background

The piece summarizes ASP Isotopes’ 3Q 2026 Form 10-Q, including revenue/EPS and segment updates (radiopharmacies, helium/LNG, isotope shipments).

Company-level read

Ticker impact

$ASPINeutralMedium confidence
Context

ASP Isotopes reports 3Q 2026 revenue of $5.12M and diluted EPS of ($0.21), with radiopharmacy growth and wider shareholder loss.

Expected impact

Likely mixed reaction, with upside from revenue growth offset by continued widening losses and weak helium/LNG economics.

Evidence & confidence

The article provides specific quarterly financials and segment margin details, but it is a 10-Q summary where the market may already be positioned for the filing.

Market effects

Highlights ongoing margin pressure in helium/LNG production until volumes rise, relevant for niche isotope and radiopharma supply-chain expectations.

No clear regional market transmission beyond US-listed small-cap biotech/industrial specialty.

Limited, as the disclosure is company-specific and not tied to a global policy or commodity shock.

Counterpoint

The widened loss may be driven by operating and interest expense timing, while gross profit improved and LNG phase 1 has commenced, which could improve margins later.

Key entities

  • ASP Isotopes Inc.

    US-listed isotope and radiopharmacy company reporting 3Q 2026 results and segment performance in a 10-Q summary.

  • Virginia Gas Project

    Phase 1 commenced commercial LNG operations, with expected margin improvement in 2027 as production volumes increase.

Related articles

$ASPIHigh

ASP Isotopes Inc. (ASPI): Quantum Leap Energy and Necsa Sign Binding Heads of Agreement to Establish Joint Venture for HALEU Production in South Africa

ASP Isotopes Inc. (ASPI) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Quantum Leap Energy and Necsa Sign Binding Heads of Agreement to Establish Joint Venture for HALEU Production in South Africa Joint Venture Supported by Offtake Agreements with TerraPower, Initial Regulatory Approvals, and Access to Site Infrastructure to enable QLE

$ASPIMed

ASP Isotopes at emerging growth conference: push to commercialize key materials

ASP Isotopes (ASPI) presented at the Emerging Growth Conference, outlining plans to commercialize projects in helium, isotopes, and nuclear fuel. CEO Paul Mann highlighted execution risks and supply shortages. The stock is down 73% from its 52-week high. The company aims to generate revenue and free cash flow over the next six months, with Phase 2 of its South African helium and LNG project fully funded. PET Labs reported 50% revenue growth in H1 2024, with expectations to double in 2026. The co

$ASPIMed

ASP Isotopes (ASPI) grows revenue to $9.3M while burning cash to expand

ASP Isotopes (ASPI) reported first-half 2026 revenue of $9.3M, up from $2.3M a year earlier, driven by specialist isotopes, new U.S. radiopharmacy operations, and helium and LNG activity tied to the Renergen acquisition, plus TerraPower collaboration revenue. Gross profit was $3.1M, but it posted a $60.7M loss from continuing operations and $40.0M operating cash outflow. Cash and short-term investments totaled $254.9M.

$ASPIMed

ASP Isotopes Secures Five-Year LNG Offtake for Virginia Gas Project

ASP Isotopes said Tetra4, a subsidiary of Renergen, signed a five-year take-or-pay LNG offtake for its Virginia Gas Project in South Africa. The deal covers about 10% of Phase 1 capacity, priced above $16 per GJ, and supports revenue certainty. Phase 1 targets ~2,500 GJ/day LNG and ~70 Mcf/day helium, with operations in Q3 2026; Phase 1 revenue could exceed $27M annually.